| Original language | English (US) |
|---|---|
| Pages (from-to) | 393-394 |
| Number of pages | 2 |
| Journal | The Lancet Neurology |
| Volume | 17 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2018 |
Bibliographical note
Funding Information:INvS chairs a steering committee for CSL Behring and received departmental honoraria for serving on scientific advisory boards for CSL Behring and Baxter. He received departmental research support from The Netherlands Organization for Scientific Research and from the Dutch Prinses Beatrix Fonds. All lecturing and consulting fees for INvS were donated to the Stichting Klinische Neurologie, a local foundation that supports research in the field of neurological disorders. INvS serves on the editorial board of the Cochrane Neuromuscular Disease Group, is a member of the organising committee of the Inflammatory Neuropathy Consortium, a standing committee of the Peripheral Nerve Society, and is a member of the Scientific Board of the Kreuth III meeting on the optimal use of plasma-derived medicinal products, especially coagulation factors and normal immunoglobulins organised under the auspices of the European Directorate for the Quality of Medicines and HealthCare. OM is a CSL employee and programme director for the PATH study. We thank Michael Tortorici for the insights in the pharmacokinetic modeling and simulations.